Cell line · CVCL_0618
Papers71
1 to 20 of 71
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E modulates vulnerability to CDC7 kinase inhibition. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. | Immunity | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Disrupting DDB2-DNA Interaction by Lapatinib Enhances Chemotherapy Sensitivity. | Int J Biol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mechanism of LINC00958 in ferroptosis of breast cancer through the SRSF1/GPX4 axis. | Hereditas | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| C19MC drives nucleolar invasion of mitochondria and meiotic nuclear division in human cancers. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer. | Cell Death Dis | 2024 | Its Methods give the RRID and name the line | PubMed | |
| eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. | Sci Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Chromatin Accessibility Landscape of Human Triple-negative Breast Cancer Cell Lines Reveals Variation by Patient Donor Ancestry. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. | Cancer Gene Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. | iScience | 2022 | Its Methods give the RRID and name the line | PubMed | |
| CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer. | Cancers (Basel) | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0618/papers